written on 21.05.2014

Top payer group shoots down Gilead's hep C drug Sovaldi on price


Individual payers aren't alone in balking at the $84,000 price for Gilead Sciences' new hepatitis C treatment Sovaldi. Now, the leading insurance trade group has joined the soloists, backing their complaints with its own.

Latest Reports